Clinical trial results:
An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents with Active Crohn's Disease Who Completed C87035 or Were Terminated from C87035 when the Study Was Stopped by UCB

Summary

EudraCT number	2017-005025-20
Trial protocol	Outside EU/EEA
Global end of trial date	27 November 2017

Results information

Result version number	v1
This version publication date	10 June 2018
First version publication date	10 June 2018

Trial information

Trial identification

Sponsor protocol code	CR0012

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	UCB BIOSCIENCES, INC.
Sponsor organisation address	8010 Arco Corporate Drive, Raleigh, United States, NC 27617
Public contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com
Scientific contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 February 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	27 November 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the longterm safety and tolerability of certolizumab pegol (CZP) in children and adolescents with moderately to severely active Crohn's disease (CD) who completed or were terminated from C87035 (NCT00899678) when the study was stopped by UCB; and to assess the longterm efficacy, pharmacokinetics (PK), and immunogenicity of CZP treatment on this population.

Protection of trial subjects:

During the conduct of the study all subjects were closely monitored.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	06 August 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	United States: 12
Worldwide total number of subjects	16
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	4
Adolescents (12-17 years)	11
Adults (18-64 years)	1

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study started to enroll patients in August 2010 and concluded in November 2017.

Pre-assignment

Screening details:

The study included an Open Label treatment period, having 16 subjects enrolled in the Safety Set (SS) shown in the Participant Flow.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Certolizumab pegol: low-dose group (weight adjusted)

Arm description:

200 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Arm type	Experimental
Investigational medicinal product name	Certolizumab pegol
Investigational medicinal product code	CZP
Other name	Cimzia
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

200 or 400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg; 100 or 200 mg for subjects 20 to < 40 kg

Arm title	Certolizumab pegol: high-dose group (weight adjusted)

Arm description:

400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 200 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Arm type	Experimental
Investigational medicinal product name	Certolizumab pegol
Investigational medicinal product code	CZP
Other name	Cimzia
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

200 or 400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg; 100 or 200 mg for subjects 20 to < 40 kg

Number of subjects in period 1	Certolizumab pegol: low-dose group (weight adjusted)	Certolizumab pegol: high-dose group (weight adjusted)
Started	4	12
Completed	3	3
Not completed	1	9
Consent withdrawn by subject	-	2
Administrative decision	1	-
Adverse event, non-fatal	-	3
Lack of efficacy	-	2
PI discretion	-	2

Baseline characteristics

Reporting groups	
Reporting group title	Certolizumab pegol: low-dose group (weight adjusted)
Reporting group description:	
200 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.	
Reporting group title	Certolizumab pegol: high-dose group (weight adjusted)
Reporting group description:	
400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 200 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.	

Reporting group values	Certolizumab pegol: low-dose group (weight adjusted)	Certolizumab pegol: high-dose group (weight adjusted)	Total
Number of subjects	4	12	16
Age categorical Units: Subjects			
<=18 years	4	11	15
Between 18 and 65 years	0	1	1
>=65 years	0	0	0
Age continuous Units: years			
arithmetic mean	13.5	13.9	
standard deviation	± 2.4	± 2.9	-
Gender categorical Units: Subjects			
Female	2	6	8
Male	2	6	8

End points

End points reporting groups

Reporting group title	Certolizumab pegol: low-dose group (weight adjusted)

Reporting group description:

200 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Reporting group title	Certolizumab pegol: high-dose group (weight adjusted)

Reporting group description:

400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 200 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Subject analysis set title	Certolizumab pegol: low-dose group (weight adjusted) – (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

200 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Subject analysis set title	Certolizumab pegol: high-dose group (weight adjusted) – (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 200 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Subject analysis set title	Certolizumab pegol: Re-Induction group – (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

If a subject had not been previously reinduced in C87035, the subject is eligible for 1 reinduction due to loss of response in CR0012. Reinduction Week 0 (first reinduction dose) is followed by Reinduction Week 2 (second dose, 2 weeks after first dose), and Reinduction Week 4 (third dose, 2 weeks after second dose). Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Subject analysis set title	Certolizumab pegol: low-dose group (weight adjusted) – (ITT)
Subject analysis set type	Intention-to-treat

Subject analysis set description:

200 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg for subjects 20 to < 40 kg. Part of the Intention-to-Treat (ITT) Population included all subjects irrespective of any protocol deviations who received at least 1 injection of the study treatment and who had at least 1 efficacy measurement after the first injection of this study.

Subject analysis set title	Certolizumab pegol: high-dose group (weight adjusted) – (ITT)
Subject analysis set type	Intention-to-treat

Subject analysis set description:

400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 200 mg for subjects 20 to < 40 kg. Part of the Intention-to-Treat (ITT) Population included all subjects irrespective of any protocol deviations who received at least 1 injection of the study treatment and who had at least 1 efficacy measurement after the first injection of this study.

Subject analysis set title	Certolizumab pegol: all dose group (weight adjusted) – (ITT)
Subject analysis set type	Intention-to-treat

Subject analysis set description:

200 mg or 400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg or 200 mg for subjects 20 to < 40 kg. Part of the Intention-to-Treat (ITT) Population included all subjects irrespective of any protocol deviations who received at least 1 injection of the study treatment and who had at least 1 efficacy measurement after the first injection of this study.

Primary: Number of subjects reporting at least one Treatment-Emergent Adverse Event (TEAE) during study treatment (up to 303 weeks)

End point title	Number of subjects reporting at least one Treatment-Emergent Adverse Event (TEAE) during study treatment (up to 303 weeks)[1]

End point description:

Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

End point type	Primary

End point timeframe:

During study treatment (up to 303 weeks)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.

End point values	Certolizumab pegol: low-dose group (weight adjusted) – (SS)	Certolizumab pegol: high-dose group (weight adjusted) – (SS)	Certolizumab pegol: Re-Induction group – (SS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	10	2	
Units: Participants				
Subjects	2	6	2	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects discontinuing treatment due to a Treatment-Emergent Adverse Event (TEAE)

End point title	Number of subjects discontinuing treatment due to a Treatment-Emergent Adverse Event (TEAE)

End point description:

Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

End point type	Secondary

End point timeframe:

During study treatment (up to 303 weeks)

End point values	Certolizumab pegol: low-dose group (weight adjusted) – (SS)	Certolizumab pegol: high-dose group (weight adjusted) – (SS)	Certolizumab pegol: Re-Induction group – (SS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	10	2	

Units: Participants				
Subjects	0	2	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects who develop anti-nuclear antibodies during the study

End point title	Number of subjects who develop anti-nuclear antibodies during the study

End point description:

Anti-nuclear antibodies (ANA) are autoantibodies. ANA titers will be determined every 12 weeks starting at Week 14, and at the Completion/Early Termination and Safety Follow-Up (SFU) Visits.

End point type	Secondary

End point timeframe:

At the time of completion or termination visit (up to 298 weeks)

End point values	Certolizumab pegol: all dose group (weight adjusted) – (ITT)			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: Participants				
Subjects	3			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study

End point title	Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study

End point description:

Anti-dsDNA are autoantibodies. Anti-dsDNA titers will be determined every 12 weeks starting at Week 14, and at the Completion/Early Termination and Safety Follow-Up (SFU) Visits.

End point type	Secondary

End point timeframe:

At the time of completion or termination visit (up to 298 weeks)

End point values	Certolizumab pegol: all dose group (weight adjusted) – (ITT)			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: Participants				
Subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects in clinical remission

End point title	Percentage of subjects in clinical remission

End point description:

Percentage of subjects in clinical remission (clinical remission is defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score ≤ 10)

End point type	Secondary

End point timeframe:

At the time of completion or termination visit (up to 298 weeks)

End point values	Certolizumab pegol: low-dose group (weight adjusted) – (ITT)	Certolizumab pegol: high-dose group (weight adjusted) – (ITT)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	9		
Units: Percentage of particpiants				
number (not applicable)				
percentage of subjects	100	44.4		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

During study treatment (up to 303 weeks)

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups

Reporting group title	Certolizumab pegol: low-dose group (weight adjusted) – (SS)

Reporting group description:

200 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 100 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Reporting group title	Certolizumab pegol: high-dose group (weight adjusted) – (SS)

Reporting group description:

400 mg administered subcutaneously every 4 weeks for subjects >= 40 kg or 200 mg for subjects 20 to < 40 kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Reporting group title	Certolizumab pegol: Re-Induction group – (SS)

Reporting group description:

If a subject had not been previously reinduced in C87035, the subject is eligible for 1 reinduction due to loss of response in CR0012. Reinduction Week 0 (first reinduction dose) is followed by Reinduction Week 2 (second dose, 2 weeks after first dose), and Reinduction Week 4 (third dose, 2 weeks after second dose). Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

Serious adverse events	Certolizumab pegol: low-dose group (weight adjusted) – (SS)	Certolizumab pegol: high-dose group (weight adjusted) – (SS)	Certolizumab pegol: Re-Induction group – (SS)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 4 (0.00%)	4 / 10 (40.00%)	1 / 2 (50.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Gastrointestinal disorders			
Crohn's disease			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 2 (50.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis viral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis viral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Certolizumab pegol: low-dose group (weight adjusted) – (SS)	Certolizumab pegol: high-dose group (weight adjusted) – (SS)	Certolizumab pegol: Re-Induction group – (SS)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)	5 / 10 (50.00%)	2 / 2 (100.00%)
Investigations			
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Haemoglobin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Ultrasound abdomen			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Vitamin D decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
Headache			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Pyrexia			

subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	4 / 10 (40.00%)	0 / 2 (0.00%)
occurrences (all)	0	5	0
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 2 (50.00%)
occurrences (all)	0	1	1
Abdominal tenderness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Anal fissure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Crohn's disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Gastritis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Oesophagitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Tooth impacted			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Respiratory, thoracic and mediastinal disorders			
Dysmenorrhoea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	1	6	0
Asthma exercise induced			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Skin and subcutaneous tissue disorders			
Ingrowing nail			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Psychiatric disorders			
Enuresis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Pain in extremity			

subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	5	0
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Joint stiffness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Ear infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Furuncle			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Localised infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 2 (0.00%)
occurrences (all)	0	2	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 June 2010	Amendment 1: - The telephone numbers for reporting serious adverse events (SAEs) during business hours or outside business hours have been indicated. - The inclusion and exclusion criteria were simplified to include subject who completed C87035. - Pregnancy due to oral contraceptive failure is not considered an SAE; the change was made to comply with Sponsor SAE reporting procedures. - An additional example of an important medical event relevant to subjects with Crohn's disease (CD) (infections that require treatment with parental antibiotics) was provided. - An inconsistency in Visit 2 vital signs compared to Schedule of Study Assessments was corrected in Section 9.6.7.
08 May 2012	Amendment 2: - Following a meeting with the Food and Drug Administration (FDA) in Apr 2012, the decision was made to stop C87035 after determining it was inadequate to address the efficacy of certolizumab pegol (CZP) for labeling in pediatric subjects. - CR0012 was amended to allow subjects ongoing in C87035 to enter CR0012 without having completed C87035, and for treatment in CR0012 to be continued until a subject reached age of 18 years or CZP is approved for use in the US by pediatric subjects with Crohn's disease (CD). - Additional updates were made to reflect the current UCB contacts, regulatory status of CZP, subject exposure, and to comply with the updated UCB definition of adverse events (AEs) of interest. - The format and style of the document was changed to comply with UCBs new document-authoring software; these changes are not specifically noted.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported